

PRIOR AUTHORIZATION POLICY

POLICY: Oncology – Tafinlar Prior Authorization Policy

- Tafinlar® (dabrafenib capsules – GlaxoSmithKline)

REVIEW DATE: 08/03/2022

OVERVIEW

Tafinlar, a BRAF inhibitor, is indicated for the following uses:¹

- **Melanoma**, in the following situations:¹
 - As a single agent for unresectable or metastatic disease with *BRAF V600E* mutation as detected by an FDA-approved test.
 - In combination with Mekinist® (trametinib tablets), for unresectable or metastatic disease with a *BRAF V600E* or *V600K* mutation, as detected by an FDA-approved test.
 - In combination with Mekinist, as adjuvant treatment of *BRAF V600E* or *V600K* mutation-positive disease as detected by an FDA-approved test, with involvement of the lymph node(s), following complete resection.
- **Metastatic or solid tumors**, in combination with Mekinist, for *BRAF V600E* mutation-positive disease, as determined by an FDA-approved test, in patients ≥ 6 years of age who have no satisfactory alternative treatment options.
- **Non-small cell lung cancer**, in combination with Mekinist for disease that has the *BRAF V600E* mutation as detected by an FDA-approved test.
- **Thyroid cancer**, in combination with Mekinist, for locally advanced or metastatic anaplastic disease with *BRAF V600E* mutation and with no satisfactory locoregional treatment options.

For the approved indications, Tafinlar has dosing for patients who are adults and for patients who are between 6 and 17 years of age and weigh ≥ 26 kg. Tafinlar is not indicated for the treatment of patients with wild-type BRAF solid tumors. Tafinlar is not indicated for treatment of patients with colorectal cancer because of the known intrinsic resistance to BRAF inhibition.

Guidelines

National Comprehensive Cancer Network (NCCN) guidelines support use in multiple cancers.

- **Central Nervous System Cancers:** Guidelines (version 1.2022 – June 2, 2022) recommend a BRAF/MEK inhibitor combination (i.e., Tafinlar/Mekinist or Zelboraf® [vemurafenib tablets]/Cotellic® [cobimetinib tablets]) for treatment of *BRAF V600E* activation mutations in adults in the following situations: adjuvant treatment of pilocytic astrocytoma, pleomorphic xanthoastrocytoma, or ganglioglioma; recurrent or progressive low-grade glioma, oligodendroglioma, or isocitrate dehydrogenase-2 (*IDH2*)-mutant astrocytoma; and recurrent glioblastoma. BRAF/MEK combination therapy is also recommended for melanoma with brain metastases.⁶ Guidelines for pediatric central nervous system (CNS) cancers (version 1.2023 – July 12, 2022) include targeted therapy with Tafinlar + Mekinist as adjuvant therapy or for recurrent or progressive disease, if the cancer has a *BRAF V600E* mutation.⁹
- **Hepatobiliary Cancers:** Guidelines (version 2.2022 – July 15, 2022) recommend Tafinlar + Mekinist for subsequent therapy for biliary tract cancers, if the patient has a *BRAF V600E* mutation.⁷
- **Histiocytic Neoplasms:** Guidelines (version 1.2022 – May 20, 2022) recommend Zelboraf (preferred) or Tafinlar (other recommended regimen) for *BRAF V600E*-mutated Erdheim-Chester disease, and for multisystem, pulmonary, or CNS Langerhans cell histiocytosis.⁵

08/03/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

- **Melanoma, Cutaneous:** Guidelines (version 2.2022 – April 11, 2022) for cutaneous disease recommend BRAF/MEK inhibitor combinations among the preferred therapies for first-line and subsequent treatment of metastatic or unresectable melanoma with a *V600*-activating mutation.² While combination BRAF/MEK inhibition is preferred, if a combination is contraindicated, monotherapy with a BRAF inhibitor is an option. Tafinlar + Mekinist is also recommended in guidelines as adjuvant therapy (including for nodal recurrence) in some patients with Stage III disease, including use post-surgery or use after complete lymph node dissection. If unacceptable toxicity to Tafinlar/Mekinist, other BRAF/MEK combinations can be considered.
- **Non-Small Cell Lung Cancer:** Guidelines (version 3.2022 – March 16, 2022) list Tafinlar + Mekinist among the first-line therapy and subsequent therapy options for tumors with a *BRAF* mutation.³ NCCN also notes that monotherapy with a BRAF inhibitor (Tafinlar or Zelboraf) is a treatment option when combination therapy is not tolerated.
- **Ovarian Cancer, Including Fallopian Tube and Primary Peritoneal Cancer:** Guidelines (version 2.2022 – July 13, 2022) recommend Tafinlar + Mekinist in various situations for recurrent carcinoma with a *BRAF V600E* mutation.⁸
- **Thyroid Cancer:** Guidelines (version 2.2022 – May 5, 2022) list Tafinlar + Mekinist as a treatment option for metastatic anaplastic thyroid cancer with a *BRAF* mutation.⁴ Tafinlar and Zelboraf are also treatment options if not amenable to radioiodine treatment for differentiated thyroid cancer (follicular, Hürthle cell, and papillary cancer subtypes) with a *BRAF V600* mutation.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Tafinlar. All approvals are provided for the duration noted below.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Tafinlar is recommended in those who meet one of the following criteria:

FDA-Approved Indications

1. **Melanoma.** Approve for 1 year if the patient meets the following (A, B, and C):
 - A) Patient meets both of the following (i and ii):
 - i. Patient is ≥ 6 years of age; AND
 - ii. Patient weighs ≥ 26 kg; AND
 - B) Patient has unresectable, advanced (including Stage III or Stage IV disease), or metastatic melanoma; AND
Note: This includes adjuvant treatment in patients with Stage III disease with no evidence of disease post-surgery.
 - C) Patient has *BRAF V600* mutation-positive disease.
2. **Metastatic or Solid Tumors.** Approve for 1 year if the patient meets the following (A, B, C, and D):
 - A) Patient meets both of the following (i and ii):
 - i. Patient is ≥ 6 years of age; AND
 - ii. Patient weighs ≥ 26 kg; AND
 - B) Patient has *BRAF V600* mutation-positive disease; AND
 - C) The medication will be taken in combination with Mekinist (trametinib tablets); AND

- D) Patient has no satisfactory alternative treatment options.
3. **Non-Small Cell Lung Cancer.** Approve for 1 year if the patient meets the following (A and B)
- A) Patient meets both of the following (i and ii):
- i. Patient is ≥ 6 years of age; AND
 - ii. Patient weighs ≥ 26 kg; AND
- B) Patient has *BRAF V600E* mutation-positive disease.
4. **Thyroid Carcinoma, Anaplastic.** Approve for 1 year if the patient meets the following (A, B, C, and D):
- A) Patient meets both of the following (i and ii):
- i. Patient is ≥ 6 years of age; AND
 - ii. Patient weighs ≥ 26 kg; AND
- B) Patient has locally advanced or metastatic anaplastic disease; AND
- C) Patient has *BRAF V600* mutation-positive disease; AND
- D) The medication will be taken in combination with Mekinist (trametinib tablets), unless intolerant.

Other Uses with Supportive Evidence

5. **Biliary Tract Cancer.** Approve for 1 year if the patient meets following (A, B, C, and D):
- A) Patient meets both of the following (i and ii):
- i. Patient is ≥ 6 years of age; AND
 - ii. Patient weighs ≥ 26 kg; AND
- B) Patient has tried at least one systemic chemotherapy regimen; AND
- C) Patient has *BRAF V600* mutation-positive disease; AND
- D) The medication will be taken in combination with Mekinist (trametinib tablets).
6. **Central Nervous System Cancer.** Approve for 1 year if the patient meets the following (A, B,C, and D):
- A) Patient meets both of the following (i and ii):
- i. Patient is ≥ 6 years of age; AND
 - ii. Patient weighs ≥ 26 kg; AND
- B) The medication is being used in one of the following situations (i, ii, or iii):
- i. Adjuvant treatment of one of the following conditions (a, b, or c):
 - a) Pilocytic astrocytoma; OR
 - b) Pleomorphic xanthoastrocytoma; OR
 - c) Ganglioglioma; OR
 - ii. Recurrent or progressive disease for one of the following conditions (a, b, c, or d):
 - a) Glioma; OR
 - b) Isocitrate dehydrogenase-2 (*IDH2*)-mutant astrocytoma; OR
 - c) Oligodendroglioma; OR
 - d) Glioblastoma; OR
 - iii. Brain metastases from melanoma; AND
- C) Patient has *BRAF V600* mutation-positive disease; AND
- D) The medication will be taken in combination with Mekinist (trametinib tablets).
7. **Histiocytic Neoplasm.** Approve for 1 year if the patient meets the following (A, B, and C):
- A) Patient meets both of the following (i and ii):
- i. Patient is ≥ 6 years of age; AND
 - ii. Patient weighs ≥ 26 kg; AND
- B) Patient meets one of the following (i or ii):

- i. Patient has Langerhans cell histiocytosis AND one of the following (a, b, or c):
 - a) Multisystem disease; OR
 - b) Pulmonary disease; OR
 - c) Central nervous system lesions; OR
 - ii. Patient has Erdheim-Chester disease; AND
 - C) Patient has *BRAF V600*-mutation positive disease.
8. **Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.** Approve for 1 year if the patient meets the following (A, B, C, and D):
 - A) Patient meets both of the following (i and ii):
 - i. Patient is ≥ 6 years of age; AND
 - ii. Patient weighs ≥ 26 kg; AND
 - B) Patient has recurrent disease; AND
 - C) Patient has *BRAF V600* mutation-positive disease; AND
 - D) The medication will be taken in combination with Mekinist (trametinib tablets).
9. **Thyroid Carcinoma, Differentiated.** Approve for 1 year if the patient meets the following (A, B, C, and D):
 - A) Patient meets both of the following (i and ii):
 - i. Patient is ≥ 6 years of age; AND
 - ii. Patient weighs ≥ 26 kg; AND
 - B) Patient has differentiated thyroid carcinoma; AND
Note: Examples of differentiated thyroid carcinoma include papillary, follicular, or Hürthle cell thyroid cancers.
 - C) Patient has disease that is refractory to radioactive iodine therapy; AND
 - D) Patient has *BRAF* mutation-positive disease.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Tafinlar is not recommended in the following situations:

1. **Colon or Rectal Cancer.** Tafinlar is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition.¹
2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Tafinlar® capsules [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2022.
2. The NCCN Melanoma Clinical Practice Guidelines in Oncology (version 3.2022 – April 11, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org/>. Accessed on July 24, 2022.
3. The NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (version 3.2022 – March 16, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org/>. Accessed on July 25, 2022.
4. The NCCN Thyroid Carcinoma Clinical Practice Guidelines in Oncology (version 2.2022 – May 5, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org/>. Accessed on July 25, 2022.
5. The NCCN Histiocytic Neoplasms Clinical Practice Guidelines in Oncology (version 1.2022 – May 20, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org/>. Accessed on July 24, 2022.
6. The NCCN Central Nervous System Cancers Clinical Practice Guidelines in Oncology (version 1.2022 – June 2, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org/>. Accessed on July 1, 2022.
7. The NCCN Hepatobiliary Cancers Clinical Practice Guidelines in Oncology (version 2.2022 – July 15, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org/>. Accessed on July 24, 2022.

8. The NCCN Ovarian Cancer, including Fallopian Tube Cancer and Primary Peritoneal Cancer Clinical Practice Guidelines in Oncology (version 2.2022 – July 13, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org/>. Accessed on July 25, 2022.
9. The NCCN Pediatric Central Nervous System Cancers Clinical Practice Guidelines in Oncology (version 1.2023 – July 12, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org/>. Accessed on July 25, 2022.